Conference Reports for NATAP

Back

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015     Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (12/29/15)   Sofosbuvir and ledipasvir for 8 weeks (SL8) in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype (GT) 1 and 4 in clinical practice - results from the German hepatitis C cohort (GECCO) - (01/20/16)   Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice - Results from the GErman hepatitis C COhort (GECCO) - (01/20/16)   Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice - Results from the GErman hepatitis C COhort (GECCO) - (01/20/16)   No Clinically Meaningful Pharmacokinetic Interactions Between HCV Inhibitors Grazoprevir/Elbasvir With Tacrolimus, Mycophenolate Mofetil, and Prednisone, But Cyclosporine Increases Grazoprevir/Elbasvir Exposures in Healthy Subjects - (01/20/16)   No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - C-EDGE C-Star Study: Grazoprevir/Elbasvir in IDUs on Opioid Antagonist Therapy - (01/20/16)   No Pharmacokinetic Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Famotidine and Pantoprazole - (01/20/16)   Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis - (01/15/16)   Merck at AASLD / HepDart 2015 - (01/14/16)   Gilead at AASLD / HepDart - Harvoni, Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir+GS9857 (6-8 weeks), Harvoni + Vedroprevir - (01/13/16)   Abbvie at AASLD / Hep Dart 2015 - (01/13/16)   BMS at AASLD - (01/13/16)   Genotype 3 at AASLD - (01/11/16)   HCV Highlights: HepDart/AASLD - Current HCV Treatments - New HCV Treatments in Development - (01/11/16)   Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis Presented at AASLD - BMS press release - (01/13/16)   The Association of Sustained Virological Response and Mortality After Interferon-based Therapy for Chronic Hepatitis C (HCV) in a Large U.S. Community-based Health Care Delivery System....SVR Reduces Mortality a Lot/Treating Early Before Cirrhosis Reduced Mortality vs in Cirrhotics - (01/13/16)   Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of Phase 2-3 Trials -2 - (01/08/16)   Antiviral Activity of TAF Against Drug-Resistant HBV Isolates in Vitro - (01/07/16)   Efficacy, Safety and Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Hepatitis C Genotype 1 Infected Non-cirrhotic Japanese Patients (Phase 2 Portion in Phase 2/3 Combined Study) - (01/04/16)   C-EDGE TN: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742) / Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection - (01/04/16)   C-EDGE Co-infection: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742)/Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment- Naïve Patients With HCV/HIV Co-infection - (01/04/16)   High Efficacy of the Combination HCV Regimen Elbasvir and Grazoprevir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Non-Cirrhotic HCV GT1b-Infected Patients: An Integrated Analysis - (01/04/16)   Safety and Tolerability of Grazoprevir/Elbasvir in Patients With Chronic Hepatitis C (HCV) Infection: Integrated Analysis of Phase 2-3 Trials - (01/04/16)   Safety and Tolerability of Grazoprevir/Elbasvir in Patients With Chronic Hepatitis C (HCV) Infection: Integrated Analysis of Phase 2-3 Trials - (01/04/16)   Predictors of Response to Elbasvir/Grazoprevir Among HCV Genotype 1 (GT1)-Infected Patients: Integrated Analysis of phase 2-3 Trials - (01/04/16)   Safety and Efficacy of GS-4774 in Patients With Chronic Hepatitis B on Oral Antiviral Therapy - (12/22/15)   Dual-Combination Therapy (NASH) Directed Against Lysyl Oxidase-Like-2 and Apoptosis Signal-Regulating Kinase 1 Potently Inhibits Fibrosis and Portal Hypertension in a New Mouse Model of PSC-Like Liver Disease/NASH - (12/22/15)   The Antiviral Response to the Toll-Like Receptor 7 Agonist GS-9620 in Preclinical Models of Chronic Hepatitis B Is Associated With an Intrahepatic Cytotoxic T Cell Transcriptional Signature - (12/22/15)   Effect of Chronic Kidney Disease on the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Subjects with HCV Genotype 1 Infection - (12/22/15)   TURQUOISE-III: 12-Week Ribavirin-Free Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir for Patients With HCV Genotype 1b and Cirrhosis - (12/22/15)   Safety and Pharmacodynamics of Oral TLR-7 Agonist GS-9620 in Patients With Chronic Hepatitis B - (12/21/15)   Functional Activation of Natural Killer and CD8+ T Cells by the Toll-Like Receptor 7 Agonist GS-9620 - (12/21/15)   Cytokines Induced by a Toll-Like Receptor 7 Agonist Potently Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (12/21/15)   Antiviral Therapy for Chronic Hepatitis B Reduces the Incidence of Hepatocellular Carcinoma Regardless of Cirrhosis Status: Analysis with Adjustment for REACH-B Risk Score - (12/21/15)   Hepatitis C Cure Leads to a Durable Decrease in Liver Stiffness..... "cirrhosis persisted in 58%" - (12/18/15)   Tenofovir Disoproxil Fumarate Reduces Perinatal Transmission of Hepatitis B Virus in Highly Viremic Mothers: A Multicenter Randomized Controlled Study - (12/18/15)   Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin for Patients With Post-Transplant HCV Recurrence - (12/18/15)   Better Work Productivity and Activity in Patients On Ombitasvir/Paritaprevir/Ritonavirand Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 (GT1) Chronic Hepatitis C - 2 - (12/18/15)   Resistance Analysis of Treatment-Naïve and DAA-Experienced Genotype 1 Patients With and Without Cirrhosis Who Received Short-Duration Treatment With Sofosbuvir/Velpatasvir + GS-9857 - (12/18/15)   Characterization of HCV Resistance From a 3-Day Monotherapy Study of GS-9857, a Novel Pangenotypic NS3/4A Protease Inhibitor - (12/18/15)   Asian Patients With Chronic Genotype 2 HCV Infection Achieve 98% Sustained Virologic Response Following 12-Week Administration of Sofosbuvir in Combination With Ribavirin: Integrated Analysis of Phase 3 Multicenter Studies - (12/18/15)   Preliminary Safety and Efficacy Results From TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin - (12/18/15)   Long-Term Efficacy of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients With or Without Cirrhosis - (12/18/15)   Safety, efficacy and tolerability in the treatment of patients with Chronic Hepatitis C and Severe Renal Impairment - (12/18/15)   Safety, efficacy and tolerability in the treatment of patients with Chronic Hepatitis C and Severe Renal Impairment - (12/16/15)   Hepatitis C cure could avoid liver transplant in some Cirrhotic patients on Dialysis listed for simultaneous liver-kidney transplantation - (12/16/15)   Effect of Renal Function on the Pharmacokinetics of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Over 2000 Subjects with HCV GT1 Infection - (12/16/15)   Efficacy and Safety of Ombitasvir/Paritaprevir/r and Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients With a History of Bleeding Disorders: Results From Phase 3 Trials - (12/16/15)   RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected Patients With Severe Renal Impairment or End-Stage Renal Disease - (12/16/15)   Projected Long-term Impact of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) in Treatment-naïve and Treatment-experienced Patients With Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease - (12/16/15)   Hepatitis C and Renal Disease: Differences in Patient Characteristics and Clinical Outcomes in the United States - (12/16/15)   Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network - (12/16/15)   Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-world Experience from the TRIO Network - (12/16/15)   Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment - (12/09/15)   Safety, Antiviral Efficacy, and Pharmacokinetics of Sofosbuvir in Patients With Severe Renal Impairment - (12/09/15)   Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)   The Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Severe Renal Impairment - (12/09/15)   Current Trends in Liver Transplantation among HCV-Infected Baby Boomer Generation in the United States: A Case for Birth-Cohort Screening - (12/09/15)   HCV Infection in Aging Baby Boomers is an Independent Predictor of Poor Outcome in Liver Transplant Recipients: An Analysis of the UNOS database - (12/09/15)   Wait Time of <6 and >18 Months Predicts HCC Recurrence after Liver Transplantation: A Multicenter Study Suggesting a Wait Time "Sweet Spot" - (12/09/15)   Curing Decompensated Wait-Listed HCV Patients with the New DAAs: Potential Significant Impact on Liver Transplant Wait List and Organ Allocation - (12/09/15)   Safety and Efficacy of Treatment With Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients With Severe Renal Impairment - (12/09/15)   Treatment with the Anti-miRNA122 Oligonucleotide RG-101 Results in a Decrease in IP-10 but Does Not affect the levels of other Cytokines in Patients with chronic Hepatitis C - (12/08/15)   A Single Dose of RG-101, a GalNAc-Conjugated Oligonucleotide Targeting miR-122, Results in Undetectable HCV RNA Levels in Chronic Hepatitis C Patients at Week 28 of Follow-up - (12/08/15)   Ledipasvir/Sofosbuvir With Ribavirin in Patients With Decompensated Cirrhosis or Liver Transplantation and HCV Infection: SOLAR-1 and -2 Trials - (12/08/15)   Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies - (12/08/15)   Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies - (12/08/15)   Cascade of Care for Hepatitis C Virus (HCV) Infection within the U.S. Department of Veterans Affairs (VA) - (12/08/15)   Safety, efficacy & Tolerability in the Treatment of Patients with Chronic HCV & Severe Renal Impairment - Hepatitis C Cure Could Avoid Liver Transplant In Some Cirrhotic Patients On Dialysis Listed for Simultaneous Liver Kidney Transplantation - (12/07/15)   Impact of Sofosbuvir-Based Regimens on Renal Function in Liver Transplant Recipients: Results of a Multicenter Study - (12/07/15)   A Novel HCV Antigen Test System for One-step Screening and Diagnosing Viremic HCV Infection Using Serum or Urine Specimens - (12/07/15)   Costs per Diagnosed Liver Disease Stage Among Individuals with Chronic Hepatitis C Virus in the Veterans Health Administration - (12/07/15)   The Cost of Making Hepatitis C a Rare Disease in the United States - (12/07/15)   Presence of Hepatitis C (HCV) Infection in Baby Boomers with Medicare Is Independently Associated with Mortality and Resource Utilization - (12/07/15)   Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial - (12/07/15)   Better Work Productivity and Activity in Patients On Ombitasvir/Paritaprevir/Ritonavirand Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 (GT1) Chronic Hepatitis C - (12/07/15)   Evolution Of Resistance Associated Variants During Initial Treatment, Viral Failure, And Re-Treatment With Directly Acting Antiviral Therapy NIH SYNERGY Trial - (12/04/15)   TELAPREVIR IN THE TREATMENT OF ACUTE HCV INFECTION IN HIV-INFECTED MEN - (12/04/15)   Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study - (12/04/15)   Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals: SWIFT-C....Harvoni 8 weeks enrolling - (12/04/15)   SOFOSBUVIR IN THE TREATMENT OF ACUTE HCV INFECTION IN HIV-INFECTED MEN - (12/04/15)   Activation of Hepatic Stellate Cells Drives the Rapid Development of Liver Fibrosis During Acute HCV Infection in HIV-infected Men - (12/04/15)   Daclatasvir Exposure Does Not Explain Lower Sustained Virologic Response Rates in Cirrhotic Patients With HCV Genotype 3 Following 12 Weeks of Daclatasvir Plus Sofosbuvir Treatment - (12/04/15)   Short-Duration Therapy With Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Plus Sofosbuvir in Patients With Chronic Hepatitis C Genotype 1 (FOURward Study) - (12/04/15)   Failure with All-oral DAA Regimens: Real-world experience from the TRIO Network. Academic and community treatment of a real-world, heterogeneous population - (12/03/15)   Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, in Patients With HCV Genotype 3 Infection - (12/03/15)   An Integrated Safety Analysis of Daclatasvir + Sofosbuvir, With or Without Ribavirin, in Patients With Chronic HCV Infection - (12/03/15)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program (advanced liver disease) - (12/03/15)   Cost-effectiveness of Combination Daclatasvir-Sofosbuvirfor Genotype 3 Chronic Hepatitis C Infection in the United States - (12/03/15)   Impact of Daclatasvir-Sofosbuvir Combination Treatment on Avoided Medical Events and Costs in Patients Infected with Genotype 3 Hepatitis C Virus - (12/03/15)   Improvement in Liver Disease Parameters Following Treatment with Daclatasvir + Sofosbuvir and Ribavirin in Patients With Chronic HCV Infection and Advanced Cirrhosis - (12/03/15)   Efficacy of Elbasvir (EBR) and Grazoprevir (GZR) in Black HCV-Infected Patients: Results of a Pooled Analysis of Phase 2/3 Studies - (12/03/15)   Value of A Cure To Society: "$256.9 Bill relative to No Treatment" - (12/03/15)   Hepatitis Debrief AASLD 2015 - (12/03/15)   Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir and Velpatasvir (GS-5816) and HIV Antiretoviral Therapies 2 - (12/02/15)   Integrated HBV DNA implicated in maintaining circulating HBsAg levels in chronically infected chimpanzees - (12/02/15)   Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens - (12/02/15)   Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA - (12/02/15)   ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B - (12/02/15)   Encapsidation and secretion of HBV RNA can be inhibited by Core Inhibitors but not by Nucleoside Analogs [NVR 3-778] - (12/02/15)   Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection - (12/02/15)   Inhibition of Hepatitis B Virus Replication by the HBV Core Inhibitor NVR 3-778 - (12/02/15)   Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: do we ask too much to DAAs? - (12/01/15)   Daclatasvir and Sofosbuvir in Patients with Recurrent HCV Following Liver Transplantation with Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol - (12/01/15)   Response-guided therapy leads to complete cure after three weeks of all-oral triple-direct acting antiviral regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI study) - (12/01/15)   Increasing Prevalence of Cirrhosis among US Adults with Chronic HCV Infection: Results from NHANES 1988-1994 and 1999-2012 - (12/01/15)   High Efficacy of Elbasvir and grazoprevir With or Without Ribavirin in 103 Treatment-Naive and Experienced Patients With HCV Genotype 4 Infection: A Pooled Analysis - (12/01/15)   Daclatasvir in Combination With Sofosbuvir With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: Interim Results of a European Multicenter Compassionate Use Program - (12/01/15)   High Rates of SVR in Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis After Treatment With Ledipasvir/Sofosbuvir and Vedroprevir With or Without Ribavirin for 8 Weeks - (12/01/15)   SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 2 Infection - (12/01/15)   SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naïve and Treatment-Experienced Patients With HCV Genotype 3 Infection - (12/01/15)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection: Interim Analysis of a French Multicenter Compassionate Use Program - (12/01/15)   Regression of Advanced Fibrosis or Cirrhosis Measured by Elastography in Patients with Chronic Hepatitis C who Achieve Sustained Virologic Response after Treatment for HCV - (12/01/15)   Highly Successful Retreatment With LDV/SOF in HCV Gt-1 Patients Who Failed Short Course LDV/SOF-Based Therapy: The NIH SYNERGY Trial - (12/01/15)   Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection - (11/30/15)   Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (11/30/15)   Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis (ASTRAL-4) - (11/30/15)   Sofosbuvir/Velpatasvir Fixed-Dose Combination for the Treatment of HCV in Patients With Decompensated Liver Disease: the Phase 3 ASTRAL-4 Study / ASTRAL 1, 2 and 3 - (11/30/15)   Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV-Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study - (11/30/15)   A Randomized Controlled Trial of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV-Infected Patients: The Phase 3 ASTRAL-2 Study - (11/30/15)   C-EDGE Co-Infected: final results from Phase 3 Study of elbasvir / grazoprevir in Patients with HCV/HIV - (11/30/15)   High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin - (11/30/15)   Treating Hepatitis C in the US: Measuring impact and value in the context of other major health interventions - (11/23/15)   Hepatitis C Disease Burden in the United States in 2015 and Beyond - (11/23/15)   Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies with or without Ribavirin: Phase 3 SVR12 Interim Results - (11/23/15)   Incidence and Determinants of Denial of DAA Therapy by Type of Insurance During the First 6 Months of the Modern HCV Treatment Era - (11/23/15)   High Virologic Response Rate in Egyptian HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial - (11/23/15)   All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study - (11/23/15)   Sofosbuvir and Velpatasvir [GS5816] for HCV Genotype 1, 2, 4, 5, and 6 Infection ASTRAL-1 - (11/23/15)   Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C - (11/23/15)   Detecting Drug-Induced Liver Injury in Patients With Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies - (11/23/15)   Incidence and Predictors of Hepatocellular Carcinoma after Sustained Viral Response in Veterans with HCV-infection - (11/23/15)   C-SWIFT Retreatment (Part B): 12 Weeks of Elbasvir/Grazoprevir with Sofosbuvir and Ribavirin Successfully Treated G1-Infected Subjects who Failed Short-Duration All-Oral Therapy - (11/23/15)   Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)   High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin - (11/23/15)   Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 1nfection (Part A of C-CREST-1 & 2) - (11/23/15)   Reduced Work Productivity, Absenteeism and Presenteeism of Patients Infected with HCV are Independently Predicted by Physical Component of Patient-Reported Outcomes - (11/23/15)   ABBVIE ANNOUNCES HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN PHASE 2 STUDIES WITH PAN-GENOTYPIC, INVESTIGATIONAL REGIMEN IN PATIENTS WITH CHRONIC HEPATITIS C - (11/19/15)   The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C - (11/19/15)   Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies - (11/19/15)   Prevalence and Impact of Baseline NSA Resistance Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - (11/19/15)   Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting® - (11/19/15)   Effect of HCV treatment on hospitalization rate: Chronic Hepatitis Cohort Study (CHeCS) - (11/19/15)   AN INTEGRATED ANALYSIS OF 402 COMPENSATED CIRRHOTIC PATIENTS WITH HCV GENOTYPE (GT) 1, 4 or 6 INFECTION TREATED WITH Elbasvir/GRAZOPREVIR - (11/19/15)   Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin for HCV Genotype 1 Patients With Decompensated Cirrhosis - (11/18/15)   No Pharmacokinetic Interaction Between HCV NS5A Inhibitor Elbasvir and Buprenorphine/Naloxone in Healthy Volunteers - (11/18/15)   Clinicians Have Multiple First-line Options for Treating HCV; Challenge is Implementation: all patients have right to be treated - (11/18/15)   Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis - (11/18/15)   Daclatasvir Exposure Alone Does Not Explain HCV Relapse in HIV-HCV Coinfected Patients Receiving Daclatasvir Plus Sofosbuvir with Ritonavir-Boosted Darunavir in the ALLY-2 Study - (11/18/15)   Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program - (11/18/15)   Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting® - (11/18/15)   Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - (11/18/15)   Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 with Cyclosporine or Tacrolimus in Healthy Subjects - (11/18/15)   Absence of Significant Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 and Methadone or Buprenorphine/Naloxone in Subjects on Opioid Maintenance Therapy ..... "no dose adjustments required" - (11/18/15)   Analysis of HCV Genotype 1 Variants Detected During Monotherapy and Combination Therapy With Next Generation HCV Direct-Acting Anti viral Agents ABT-493 and ABT-530 "........COMBINATION THERAPY (SURVEYOR-I PART 1, PHASE 2 DOSE-RANGING STUDY) .....All patients with baseline NS3 or NS5A variants achieved SVR12 (Study SVR12: 99%)" - (11/18/15)   Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Chronic HCV Genotype 4 Infection Without Cirrhosis and With Compensated Cirrhosis in Egypt (AGATE-II) - (11/18/15)   Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Infection and Cirrhosis (AGATE-I) - (11/18/15)   Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)   100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or -Experienced Patients With the Combination of ABT-493 and ABT-530 for 8 Weeks (SURVEYOR-I)....[8 weeks] - (11/17/15)   QUARTZ-I: Retreatment of HCV Genotype 1 DAA-failures With Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir - (11/17/15)   A Phase 3 Double-Blind Placebo-Controlled Evaluation of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Genotype 1, 2, 4, 5, 6 HCV-Infected Patients: Results of the ASTRAL-1 Study - (11/17/15)   The Combination of Elbasvir and Grazoprevir ± RBV Is Highly Effective for the Treatment of GT1a-Infected Patients - (11/17/15)   High Prevalence of co-morbidities and complex polyharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C - (11/17/15)   Sofosbuvir With Velpatasvir (GS-5816) in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)   Sofosbuvir Plus Velpatasvir (GS-5816) Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial - (11/17/15)   AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis - (11/16/15)   AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis - (11/16/15)   Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies - (11/16/15)   Gilead Presents New Data at The Liver Meeting 2015 - (11/16/15)   Safety and Efficacy of Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV Genotype 3 Infection: Interim Results of a Multicenter European Compassionate Use Program - (11/16/15)   Sofosbuvir/Velpatasvir + GS-9857 for 6 or 8 Weeks in Genotype 1 or 3 HCV-Infected Patients - (11/16/15)   C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)   SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease - (11/16/15)   SURVEYOR-I: 98% - 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null-Responders with the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 - (11/16/15)   Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - (11/16/15)   Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study - (11/16/15)   (VA) Effectiveness of Ledipasvir/Sofosbuvir in Treatment Naïve Genotype 1 Patients Treated in Routine Medical Practice - (11/16/15)   Failure with All-Oral DAA Regimens:Academic and Community Treatment of a Real-World Population from the TRIO Network - (12/16/15)   (HCV-TARGET) - Treatment Outcomes With 8, 12 and 24 Week Regimens of Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Infection: Analysis of a Multicenter Prospective, Observational Study - (12/03/15)   Rectal Shedding of HCV in HIV/HCV co-infected Men - (11/16/15)   Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiretroviral Regimens in Subjects With HCV/HIV Coinfection - (11/16/15)